|
|
|
|
| LEADER |
01464nam a2200325 u 4500 |
| 001 |
EB001865389 |
| 003 |
EBX01000000000000001029469 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
190504 r ||| eng |
| 245 |
0 |
0 |
|a Patient group input submissions: Omalizumab (Xolair) for asthma, severe persistent
|h Elektronische Ressource
|
| 246 |
3 |
1 |
|a Omalizumab (Xolair) for asthma, severe persistent
|
| 246 |
3 |
1 |
|a Patient group input submission to CADTH
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2017, 2017 Sep
|
| 300 |
|
|
|a 1 PDF file (13 pages)
|b illustrations
|
| 653 |
|
|
|a Patient Participation
|
| 653 |
|
|
|a Canada
|
| 653 |
|
|
|a Asthma / drug therapy
|
| 653 |
|
|
|a Treatment Outcome
|
| 653 |
|
|
|a Patient Satisfaction
|
| 653 |
|
|
|a Health Surveys
|
| 653 |
|
|
|a Omalizumab / therapeutic use
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH common drug review
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK533754
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 700
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a Questionnaires were promoted via several Canadian respiratory health agencies to asthma patients or those suffering with severe, persistent asthma-related symptoms to gather input on the effectiveness of omalizumab in the treatment of the disease
|